• In 2025, Twist Bioscience’s CEO and Chair Emily M. Leproust received total compensation of US$13,781,570, while recent insider activity showed only stock sales and no purchases alongside adjustments in institutional holdings.
• At the same time, multiple brokerage firms reiterated positive views on Twist Bioscience’s semiconductor-based DNA synthesis platform, collectively maintaining an “Outperform” stance backed by confidence in its synthetic biology technology.
• Building on this renewed analyst optimism around Twist Bioscience’s DNA platform, we’ll now consider how it reshapes the company’s investment narrative.

These 18 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Twist Bioscience Investment Narrative Recap

To own Twist Bioscience, you need to believe that its semiconductor-based DNA synthesis platform can translate into a durable, high-margin business despite continued losses and customer concentration. The recent jump in CEO compensation and insider selling does not materially change the key near term catalyst, which remains progress toward adjusted EBITDA breakeven, or the biggest risk, which is the potential need for future capital if losses persist.

Among recent announcements, Twist’s Q4 2025 results and full year revenue of US$376.57 million, alongside a net loss of US$77.67 million, are most relevant here, because they frame how quickly the business might scale toward profitability. These figures sit in the background as analysts reiterate positive views on the company’s DNA platform, sharpening the contrast between technology enthusiasm and the ongoing earnings drag.

Yet beneath the excitement around the DNA platform, investors should also be aware that...

Twist Bioscience's narrative projects $575.2 million revenue and $92.4 million earnings by 2028. This requires 16.7% yearly revenue growth and a $177.6 million earnings increase from -$85.2 million today.

Uncover how Twist Bioscience's forecasts yield a $35.62 fair value, in line with its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community cluster between US$35.47 and US$42, highlighting how differently private investors assess Twist’s potential. You can set these views against the company’s continued losses and the risk of a future capital raise, then decide which assumptions about Twist’s path to breakeven feel most realistic to you.

Explore 3 other fair value estimates on Twist Bioscience - why the stock might be worth just $35.47!

Build Your Own Twist Bioscience Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Twist Bioscience research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Twist Bioscience research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Twist Bioscience's overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 39 companies in the world exploring or producing it. Find the list for free.
• We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.